Clinical Study On The Significance Of Airway Hyperresponsiveness Monitoring In The Adjustment Of Combined Therapy For Asthmatic Patients

Objective To monitor the changes of symptom scores,airway hyperreponsiveness(AHR,represented by PC₃₅sGaw),FEV₁% and PEF% in patients with mild and moderate persistent asthma who received combined therapy of inhaled corticosteroids(ICS) and long-acting β₂ agonists(LABA) and evaluate the clinical significance of PC₃₅sGaw as a guide in the adjustment of asthma stepwise therapy.Methods The subjects met the enroll standards were allocated randomly to group A,B,and C. The initiative regimens for all patients in the first three months included ICS (fluticasone) plus LABA (salmeterol).The subjects in group A sustained a fixed dosage for eighteen months while those in group B tailored the dose or withdraw therapy according to asthma clinical control level,ie.well or total control. Otherwise,the regimens for the subjects in group C were step-down or withdrawn according to PC₃₅sGaw besides asthma clinical control. All subjects were followed-up for eighteen months and the symptom scores, PC₃₅sGaw,FEVl% and PEF% were measured...